İDİpek Güngör Doğan

İpek Güngör Doğan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


İpek Güngör Doğan has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical and radiological features of anti-MOG-associated cerebral cortical encephalitis

    by Hazal Ceren Manazoğlu, Serkan Demir, İpek Güngör Doğan, Damla Çetinkaya Tezer, Kadriye Ağan, Ahmet Kasım Kılıç, Serkan Özakbaş, Furkan Sarıdaş, Rabia Koç, Nevin Pazarcı, et al.

  • Exploring the Type 4 Cerebrospinal Fluid Oligoclonal Band Pattern: Clinical and Paraclinical Features with Diagnostic Implications

    by Duygu Arslan Mehdiyev, Meryem Tuba Sönmez, Sedat Şen, Sümeyye Koç, Gökhan Arslan, Nur Yüceyar, Furkan Sarıdaş, Emine Rabia Koç, Ömer Faruk Turan, İrem Taşcı, et al.

  • Beyond serology: clinical and prognostic determinants in patients with dual AQP4-IgG and MOG-IgG seropositivity

    by Ipek Gungor Dogan, Sedat Sen, Damla Cetinkaya Tezer, Sude Kendirli Aslan, Haluk Gumus, Bilge Piri Cinar, Nuray Bilge, Ozlem Ethemoglu, Ferah Kizilay, Cavit Boz, et al.

  • Open Access

    Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder

    by Emine Rabia Koc, Mehmet Fatih Yetkin, Furkan Saridas, Omer Faruk Turan, Serhan Sevim, Murat Terzi, Sedat Sen, Melih Tutuncu, Ugur Uygunoglu, Murat Kurtuncu, et al.

    Objective: To evaluate the real-world effectiveness and safety of eculizumab in patients with AQP4-IgG–positive neuromyelitis optica spectrum disorder (NMOSD) and to identify predictors of disability outcomes. Methods: This multinational, retrospective cohort study analyzed data from 46 patients across 26 centers. The outcomes included the annualized relapse rate (ARR), relapse-free status, change in expanded disability status scale (EDSS) scores, and adverse events. To identify predictors of EDSS improvement or worsening, patients were stratified into subgroups (improved vs. stable/worsened) at each follow-up time point and compared based on demographic, clinical, and radiological variables. Results: This retrospective cohort study included 46 patients with AQP4-IgG-positive NMOSD from 26 centers, followed for a mean of 27.3 months. The mean ARR significantly decreased from 1.1 in the 2 years pre-treatment to 0.1 during eculizumab therapy. The relapse-free rate increased from 6.5% pre-treatment to 80.4%. Mean EDSS scores improved from 4.2 at baseline to 3.6 at 24 months. The presence of area postrema syndrome was associated with a favorable prognosis, while the presence of spinal attacks was associated with a poor prognosis at 12 months. Adverse events occurred in 7 patients (18.9%), leading to permanent discontinuation in only two. Conclusion: Eculizumab demonstrated robust real-world effectiveness in reducing relapse rates and stabilizing disability, with an acceptable safety profile. Clinical outcomes may be influenced by attack phenotype, underscoring the importance of early intervention.


  • Differential Metacognitive Profiles in Relapsing–Remitting and Progressive Multiple Sclerosis: Associations with Fatigue, Cognition, and Perceived Disability

    by Ozlem Totuk, Merve Turkkol, Hasan Can Gudek, Ipek Gungor Dogan, Damla Cetinkaya Tezer, Sevki Sahin, Serkan Demir

    Objective: This study examined metacognitive belief profiles in individuals with multiple sclerosis (MS) and their associations with cognitive, emotional, and functional outcomes. Specifically, we compared relapsing–remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS) to determine whether distinct metacognitive patterns characterize different disease phenotypes. Method: A total of 504 participants (75.6% RRMS, 9.9% SPMS, 14.5% PPMS) were recruited from a neurology clinic. Participants completed the Metacognitions Questionnaire-30 (MCQ-30), Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI), Modified Fatigue Impact Scale (MFIS), Expanded Disability Status Scale (EDSS), Short Form-12 (SF-12), and Occupational Self-Assessment (OSA). Group differences were examined using ANOVA, correlations via Pearson coefficients, and hierarchical and ordinal regression models. Results: Progressive phenotypes, particularly PPMS, showed significantly higher maladaptive metacognitive beliefs than RRMS. RRMS individuals exhibited greater cognitive self-consciousness and need for control, whereas PPMS was associated with lower cognitive confidence and stronger negative beliefs about uncontrollability. No subtype differences emerged in positive beliefs. Maladaptive metacognition correlated with lower cognitive performance, greater fatigue, depressive symptoms, reduced quality of life, and lower self-efficacy. In regression models, depression was the strongest negative predictor of self-efficacy, while cognitive self-consciousness was a positive predictor. Clinical and psychological variables together explained 60% of the variance in self-efficacy. Metacognitive beliefs and fatigue also predicted higher neurological disability (EDSS). Conclusions: Metacognitive belief patterns differ across MS phenotypes and significantly impact both functional and neurological outcomes. These findings support incorporating metacognitive assessment into routine MS care and underscore the need for tailored psychological interventions addressing cognitive-emotional regulation.

  • Is there a role of MOG antibodies in idiopathic intracranial hypertension: A comparative analysis with optic neuritis-MOG antibody associated disease

    by Guldeniz Cetin Erci, Tugba Gencaga Atakan, Mesut Yigit, Ozlem Gulacti, Sibel Balci, Hasan Can Gudek, Damla Cetinkaya Tezer, Ipek Gungor Dogan, Serkan Demir

  • Open Access

    Sexual dysfunction in multiple sclerosis: prevalence, risk factors, and impact on quality of life in a large cohort study

    by Ozlem Totuk, Merve Türkkol, Feyzullah Yadi, Hasan Can Güdek, Güldeniz Çetin Erci, İpek Güngör Doğan, Damla Çetinkaya Tezer, Sevki Sahin, Serkan Demir

    Sexual dysfunction (SD) is a prevalent but underreported symptom in people with multiple sclerosis (pwMS), significantly affecting quality of life (QoL). Despite its clinical relevance, SD is often overlooked during routine care. This study aimed to determine the prevalence of SD, identify associated risk factors, assess its impact on depression and QoL, and explore help-seeking behaviors among pwMS. A cross-sectional study was conducted with 504 pwMS followed at a tertiary MS clinic between November 2023 and May 2024. Data on demographics, disease characteristics, and medications were collected. The Arizona Sexual Experiences Scale (ASEX) was used to assess SD, the Beck Depression Inventory (BDI) for depression, and the Short Form-12 (SF-12) for QoL. EDSS scores were used to evaluate disability. Statistical analyses included t-tests, ANOVA, chi-square, correlation analyses, and univariate and multivariate logistic regression, with significance set at p < 0.05. SD was identified in 69.0% of patients (73.9% of women, 57.6% of men). SD was significantly associated with female gender (p = 0.001), older age (p = 0.006), higher EDSS scores (p = 0.046), and increased depression levels (r = 0.38). SF-12 scores were significantly lower among those with SD (p < 0.001). In multivariate analysis, female gender (aOR = 2.01, p = 0.002) and higher BDI scores (aOR = 1.09, p < 0.001) remained independently associated with SD, while age and EDSS did not. No significant associations were found between SD and MS type, disease duration, or type of disease-modifying therapy. Only 9.8% of patients with SD sought medical help, while 83.1% did not seek support. SD is highly prevalent among pwMS and is closely linked to age, disability, depression, and reduced QoL. Depression emerged as a strong independent predictor. Despite this burden, most patients do not seek help. Multidisciplinary approaches and routine screening are essential to address SD in clinical settings.


  • The prevalence and clinical significance of trigeminal neuralgia in patients with multiple sclerosis

    by İpek Güngör Doğan, Ebru Kaya, Sude Kendirli Aslan, Damla Çetinkaya Tezer, Serkan Demir

    Background & Objective: Trigeminal neuralgia (TN) is a debilitating neuropathic pain disorder characterized by sudden and intense episodes of facial pain, significantly impairing patients’ quality of life. Diagnosing TN is particularly challenging in multiple sclerosis (MS), a chronic autoimmune, demyelinating, and neurodegenerative disease affecting the central nervous system. TN in MS is predominantly caused by demyelination, axonal loss, inflammation, and brainstem lesions. However, the overlapping symptoms of TN and other craniofacial pain disorders often lead to underdiagnosis and treatment delays. This study aimed to determine the prevalence and clinical characteristics of TN in MS patients, in a cohort of Turkish patients, with a focus on diagnostic challenges and treatment patterns. Methods: A single-center, cross-sectional survey was conducted, systematically assessing headache and facial pain symptoms among MS patients treated at the Sancaktepe Neuroimmunology Clinic, Istanbul, Turkey. Results: The findings revealed a significant prevalence of TN (39.8%) in MS patients, with a female predominance and a mean diagnostic delay of 14 months. Despite the availability of effective treatments, a substantial proportion of patients remained undiagnosed and untreated. Conclusion: There is urgent need to integrate routine TN screening into MS patient care to improve timely diagnosis and effective management. The study underscores the importance of a multidisciplinary approach in addressing this overlooked comorbidity, ultimately enhancing the quality of life for MS patients.

  • Open Access

    Exploring Social Cognition Sub‐Domains and Predictors in Multiple Sclerosis: A Cross‐Sectional Study

    by Ozlem Totuk, Merve Turkkol, Ebru Hatun Uludaşdemir, Hasan Can Güdek, Guldeniz Cetin Erci, Ipek Gungor Dogan, Damla Cetinkaya Tezer, Sevki Sahin, Serkan Demir

    Background and purpose: Social cognition (SC) is increasingly recognized as a key cognitive domain affected in multiple sclerosis (MS), yet its sub‐domains and clinical correlates remain underexplored. This study aimed to assess different SC sub‐domains and identify their cognitive, emotional, and demographic predictors in people with MS (pwMS). Methods: This cross‐sectional study included 93 pwMS and 34 HCs. Assessments included the Reading the Mind in the Eyes Test (RMET) for emotion recognition, the Trail Making Test (TMT) for executive function, the Tromso Social Intelligence Scale (TSIS) for nonverbal understanding, the Implied Meaning Test (IMT) for implicit understanding, the Social‐Emotional Competence Scale for adaptability, the Barratt Impulsiveness Scale for impulsivity, the Stroop Test for inhibition, the Beck Depression Inventory (BDI) for depression, the Montreal Cognitive Assessment (MoCA) for cognition, and the Short Form‐12 (SF‐12) for quality of life (QoL). Multiple regression analyses were conducted to identify independent predictors of SC performance. Results: PwMS, particularly those with progressive MS, exhibited significantly lower SC performance across all sub‐domains compared to HCs. Regression analyses revealed that lower MoCA scores, higher BDI scores, and lower educational attainment were significant predictors of impaired SC, while disease duration and gender were not. Notably, SC deficits were also observed in cognitively preserved individuals, suggesting the relative independence of SC impairments. Conclusion: SC impairment is a distinct and clinically relevant feature of MS, associated with both cognitive and emotional factors. Routine SC screening may enhance patient care by informing personalized interventions. Future research should include larger cohorts, longitudinal designs, and practical SC assessment tools for clinical use.


  • Open Access

    Risk of Hepatitis B Virus Reactivation in Patients with Neurological Diseases Receiving Anti-CD20 Therapies

    by İpEk Gungor Dogan, Feyzullah Yadi, Damla Çetinkaya Tezer, Serkan Demir

    Objective: Anti-CD20 therapies, including ocrelizumab, rituximab, and ofatumumab, are widely used in treating immune-mediated neurological diseases. However, these therapies may increase the risk of hepatitis B virus (HBV) reactivation, particularly in patients with prior HBV exposure. Despite the recognized preventive measures for managing HBV reactivation, specific data regarding the safety of anti-CD20 therapies in this context remain limited. This retrospective study aims to evaluate the risk of HBV reactivation among patients with neurological disorders treated with anti-CD20 therapies in a single-center cohort from Türkiye. Methods: We reviewed the records of 580 patients who received at least one dose of anti-CD20 therapies between July 2018 and March 2024. HBV serological markers were assessed at baseline and during follow-up. Patients were stratified based on HBV serostatus, and antiviral prophylaxis rates were documented. Serological follow-up data were reviewed for seroconversion. Results: Of the patients, 12.24% showed anti-HBc positivity, with higher rates in the ocrelizumab group (15.57%) compared to rituximab (8.08%) and none in the ofatumumab group. Among the anti-HBs positive group, the prophylaxis rate was 78%, while it was 100% in the anti-HBs negative side. No seroconversion cases were observed, regardless of prophylaxis status. Conclusions: Our findings indicate that anti-CD20 therapies do not pose a detectable risk of HBV reactivation in patients with immune-mediated neurological disorders, even when antiviral prophylaxis is not given to those who are anti-HBs positive. However, further prospective studies with larger cohorts must confirm these results and improve HBV management in this patient population.